{"downloaded": true, "htmlmade": false, "full": {"id": "30074259", "source": "MED", "pmid": "30074259", "pmcid": "PMC6221102", "fullTextIdList": {"fullTextId": "PMC6221102"}, "doi": "10.1002/ajh.25238", "title": "Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.", "authorString": "Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O'Connell A, Chan G, Schroeder MA.", "authorList": {"author": [{"fullName": "Cortes JE", "firstName": "Jorge E", "lastName": "Cortes", "initials": "JE", "authorId": {"@type": "ORCID", "#text": "0000-0002-8636-1071"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas."}}}, {"fullName": "Douglas Smith B", "firstName": "B", "lastName": "Douglas Smith", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland."}}}, {"fullName": "Wang ES", "firstName": "Eunice S", "lastName": "Wang", "initials": "ES", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York."}}}, {"fullName": "Merchant A", "firstName": "Akil", "lastName": "Merchant", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California."}}}, {"fullName": "Oehler VG", "firstName": "Vivian G", "lastName": "Oehler", "initials": "VG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Fred Hutchinson Cancer Research Center, Seattle, Washington."}}}, {"fullName": "Arellano M", "firstName": "Martha", "lastName": "Arellano", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia."}}}, {"fullName": "DeAngelo DJ", "firstName": "Daniel J", "lastName": "DeAngelo", "initials": "DJ", "authorId": {"@type": "ORCID", "#text": "0000-0001-7865-2306"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts."}}}, {"fullName": "Pollyea DA", "firstName": "Daniel A", "lastName": "Pollyea", "initials": "DA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado."}}}, {"fullName": "Sekeres MA", "firstName": "Mikkael A", "lastName": "Sekeres", "initials": "MA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Leukemia Program, Cleveland Clinic, Cleveland, Ohio."}}}, {"fullName": "Robak T", "firstName": "Tadeusz", "lastName": "Robak", "initials": "T", "authorId": {"@type": "ORCID", "#text": "0000-0002-3411-6357"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Medical University of Lodz, Lodz, Poland."}}}, {"fullName": "Ma WW", "firstName": "Weidong Wendy", "lastName": "Ma", "initials": "WW", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Pfizer Oncology, New York, New York."}}}, {"fullName": "Zeremski M", "firstName": "Mirjana", "lastName": "Zeremski", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Pfizer Oncology, New York, New York."}}}, {"fullName": "Naveed Shaik M", "firstName": "M", "lastName": "Naveed Shaik", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Pfizer Oncology, New York, New York."}}}, {"fullName": "Douglas Laird A", "firstName": "A", "lastName": "Douglas Laird", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Pfizer Oncology, New York, New York."}}}, {"fullName": "O'Connell A", "firstName": "Ashleigh", "lastName": "O'Connell", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Pfizer Oncology, New York, New York."}}}, {"fullName": "Chan G", "firstName": "Geoffrey", "lastName": "Chan", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Pfizer Oncology, New York, New York."}}}, {"fullName": "Schroeder MA", "firstName": "Mark A", "lastName": "Schroeder", "initials": "MA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Oncology, Washington University School of Medicine, St Louis, Missouri."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-7865-2306"}, {"@type": "ORCID", "#text": "0000-0002-3411-6357"}, {"@type": "ORCID", "#text": "0000-0002-8636-1071"}]}, "dataLinksTagsList": {"dataLinkstag": ["related_data", "supporting_data", "altmetrics"]}, "journalInfo": {"issue": "11", "volume": "93", "journalIssueId": "2740721", "dateOfPublication": "2018 Nov", "monthOfPublication": "11", "yearOfPublication": "2018", "printPublicationDate": "2018-11-01", "journal": {"title": "American journal of hematology", "ISOAbbreviation": "Am J Hematol", "medlineAbbreviation": "Am J Hematol", "NLMid": "7610369", "ISSN": "0361-8609", "ESSN": "1096-8652"}}, "pubYear": "2018", "pageInfo": "1301-1310", "abstractText": "Glasdegib is a Hedgehog pathway inhibitor. This ongoing, open-label, phase 2 study (NCT01546038) evaluated glasdegib plus cytarabine/daunorubicin in patients with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Patients received glasdegib 100 mg orally, once daily in continuous 28-day\u2009cycles from day -3, with intravenous cytarabine 100\u2009mg/m<sup>2</sup> on days 1-7 and daunorubicin 60\u2009mg/m<sup>2</sup> on days 1-3. Patients in remission then received consolidation therapy (2-4 cycles of cytarabine 1 g/m<sup>2</sup> twice daily on days 1, 3, 5 of each cycle), followed by maintenance glasdegib (maximum 6 cycles). Primary endpoint was complete remission (CR) in patients aged \u226555\u2009years. Secondary endpoints included overall survival (OS), safety and outcome by mutational status. Patients had a median (range) age of 64.0 (27-75) years, 60.0% were male, and 84.5% were white. In 69 evaluable patients, 46.4% (80% confidence interval [CI]: 38.7-54.1) achieved investigator-reported CR. Among patients \u226555\u2009years old (n =\u200960), 40.0% (80% CI 31.9-48.1) achieved CR. Among all 69 patients, median OS was 14.9 (80% CI 13.4-19.3) months, with 12-month survival probability 66.6% (80% CI 58.5-73.4). The most common treatment-related adverse events (\u226550% patients) were diarrhea and nausea. There were no significant associations between mutational status (12 genes) and clinical response, suggesting potential benefit across diverse molecular profiles. Glasdegib plus cytarabine/daunorubicin was well tolerated and associated with clinical activity in patients with untreated AML or high-risk MDS. A randomized phase 3 trial of glasdegib in combination with chemotherapy (7 + 3 schedule) is ongoing.", "affiliation": "Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Journal Article"]}, "grantsList": {"grant": [{"grantId": "P01 CA066996", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "P01 CA066996", "agency": "National Cancer Institute", "acronym": "NCI NIH HHS", "orderIn": "0"}, {"agency": "Pfizer Inc.", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Myelodysplastic Syndromes", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CO", "qualifierName": "complications", "majorTopic_YN": "N"}, {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Phenylurea Compounds", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Benzimidazoles", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Daunorubicin", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Cytarabine", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Remission Induction", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Myeloid, Acute", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CO", "qualifierName": "complications", "majorTopic_YN": "N"}, {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Consolidation Chemotherapy", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Maintenance Chemotherapy", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}]}, "chemicalList": {"chemical": [{"name": "Benzimidazoles", "registryNumber": "0"}, {"name": "Phenylurea Compounds", "registryNumber": "0"}, {"name": "Daunorubicin", "registryNumber": "ZS7284E0ZP"}, {"name": "Cytarabine", "registryNumber": "04079A1RDZ"}, {"name": "glasdegib", "registryNumber": "K673DMO5H9"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1002/ajh.25238"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6221102"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6221102?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "28", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "Y", "dbCrossReferenceList": {"dbName": "CHEBI"}, "hasLabsLinks": "Y", "license": "cc by-nc-nd", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-08-19", "dateOfCreation": "2018-08-04", "firstIndexDate": "2018-08-03", "fullTextReceivedDate": "2020-07-09", "dateOfRevision": "2021-01-09", "electronicPublicationDate": "2018-09-09", "firstPublicationDate": "2018-09-09"}, "htmllinks": "https://europepmc.org/articles/PMC6221102", "abstract": "Glasdegib is a Hedgehog pathway inhibitor. This ongoing, open-label, phase 2 study (NCT01546038) evaluated glasdegib plus cytarabine/daunorubicin in patients with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Patients received glasdegib 100 mg orally, once daily in continuous 28-day\u2009cycles from day -3, with intravenous cytarabine 100\u2009mg/m<sup>2</sup> on days 1-7 and daunorubicin 60\u2009mg/m<sup>2</sup> on days 1-3. Patients in remission then received consolidation therapy (2-4 cycles of cytarabine 1 g/m<sup>2</sup> twice daily on days 1, 3, 5 of each cycle), followed by maintenance glasdegib (maximum 6 cycles). Primary endpoint was complete remission (CR) in patients aged \u226555\u2009years. Secondary endpoints included overall survival (OS), safety and outcome by mutational status. Patients had a median (range) age of 64.0 (27-75) years, 60.0% were male, and 84.5% were white. In 69 evaluable patients, 46.4% (80% confidence interval [CI]: 38.7-54.1) achieved investigator-reported CR. Among patients \u226555\u2009years old (n =\u200960), 40.0% (80% CI 31.9-48.1) achieved CR. Among all 69 patients, median OS was 14.9 (80% CI 13.4-19.3) months, with 12-month survival probability 66.6% (80% CI 58.5-73.4). The most common treatment-related adverse events (\u226550% patients) were diarrhea and nausea. There were no significant associations between mutational status (12 genes) and clinical response, suggesting potential benefit across diverse molecular profiles. Glasdegib plus cytarabine/daunorubicin was well tolerated and associated with clinical activity in patients with untreated AML or high-risk MDS. A randomized phase 3 trial of glasdegib in combination with chemotherapy (7 + 3 schedule) is ongoing.", "pdflinks": "https://europepmc.org/articles/PMC6221102?pdf=render", "journaltitle": "American journal of hematology", "authorinfo": ["Cortes JE", "Douglas Smith B", "Wang ES", "Merchant A", "Oehler VG", "Arellano M", "DeAngelo DJ", "Pollyea DA", "Sekeres MA", "Robak T", "Ma WW", "Zeremski M", "Naveed Shaik M", "Douglas Laird A", "O'Connell A", "Chan G", "Schroeder MA"], "title": "Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results."}